Zacks Investment Research
07 Aug 2026, 15:51 UTC · 1h ago
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
07 Aug 2026, 15:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Intellia's phase III HAELO study for lonvo-z met its primary and all key secondary endpoints, reducing attacks by 87% compared to placebo. — Positive phase III results are the most critical catalyst for biotech firms, significantly increasing the probability of FDA approval and commercial success.
+0.80Intellia expects the U.S. commercial launch of lonvo-z for hereditary angioedema (HAE) in the first half of 2027. — Provides a concrete timeline for the transition from a research-stage company to a commercial-stage entity with potential revenue.
+0.50The company's cash, cash equivalents, and marketable securities totaled $628.4 million as of June 30, 2026, expected to fund operations into 2028. — Strong liquidity reduces immediate dilution risk and ensures the company can reach its key commercial milestones.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
Intellia reported second-quarter 2026 revenues of $7.7 million, missing the Zacks Consensus Estimate of $15 million. — While expected for pre-commercial biotechs, a significant revenue miss relative to estimates is fundamentally negative.
-0.30Intellia reported a second-quarter loss of 80 cents per share, narrowing 18.4% from the prior year. — A narrowing loss suggests better cost control or efficiency, though it remains a net loss.
+0.10Which stocks this story touches
The company narrowed its losses and reported positive Phase III trial results for lonvo-z, despite missing revenue estimates.
Mentioned as a source of declining collaboration revenues for Intellia.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
